Trial Profile
A phase I trial of zika virus vaccine
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 29 Apr 2016
At a glance
- Drugs Zika virus vaccine (Primary)
- Indications Zika virus infection
- Focus Adverse reactions; First in man
- 29 Apr 2016 New trial record
Most Recent Events
Trial Overview
Purpose
This trial will investigate zika virus vaccine.
Diseases Treated
| Indication | Qualifiers | Patient Segments |
|---|---|---|
| Zika virus infection | prevention | - |
Subjects
- Subject Type volunteers
- Sex male & female
- Age Group adult
Patient Inclusion Criteria
Healthy volunteers
Trial Details
Organisations
- Affiliations Imutex
Trial Dates
Other Details
- Design prospective
- Phase of Trial Phase I
- Location USA
- Focus Adverse reactions; First in man
Interventions
| Drugs | Route | Formulation |
|---|---|---|
| Zika virus vaccinePrimary Drug |
-
|
-
|
Zika virus vaccine
Trial Centres
Centres
| Centre Name | Location | Trial Centre Country |
|---|---|---|
| National Institute of Health Clinical Center | Bethesda, Maryland | USA |
Trial History
| Event Date | Event Type | Comment |
|---|---|---|
| 29 Apr 2016 | New trial record | New trial record Updated 29 Apr 2016 |
References
-
hVIVO. hVIVO Announces a Joint Venture Investment with the SEEK Group to Develop Vaccines against Flu and Zika Infections. Media-Rel 2016;.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG